2-(6-fluoronaphthalen-1-yl)acetonitrile | 70631-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(6-fluoronaphthalen-1-yl)acetonitrile
• 英文别名: 6-Fluoronaphthalene-1-acetonitrile
• CAS: 70631-48-0
• 化学式: C₁₂H₈FN
• 分子量: 185.201
• InChiKey: KEDMMAUTROBFDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS DE SULFONAMIDE ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015158313A1

  公开（公告）日：2015-10-22

  Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.

  本文提供了磺胺衍生物或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药用可接受的盐或其前药，以及它们用于治疗阿尔茨海默病的用途。本文还提供了含有这些化合物的药物组合物，并使用这些化合物或其药物组合物来管理或治疗5-HT6受体介导的疾病，特别是用于制造治疗或管理阿尔茨海默病的药物。
• SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：EP3134392B1

  公开（公告）日：2019-01-02
• Sulfonamide Derivatives And Pharmaceutical Applications Thereof
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US20170037017A1

  公开（公告）日：2017-02-09

  Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT 6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
• US9840482B2
  申请人：——

  公开号：US9840482B2

  公开（公告）日：2017-12-12